Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of GANX will decline by -9.61% over the next 2 Weeks and hit $1.55 by Wednesday, September 30, 2026. In that time frame, GANX's share price is expected to range between $1.45 and $1.66.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper |
|---|---|---|---|
| Sep 30, 2026 | 1.45 | 1.55 | 1.66 |
| Sep 29, 2026 | 1.48 | 1.57 | 1.66 |
| Sep 28, 2026 | 1.45 | 1.55 | 1.64 |
| Sep 25, 2026 | 1.49 | 1.59 | 1.68 |
| Sep 24, 2026 | 1.53 | 1.63 | 1.72 |
| Sep 23, 2026 | 1.54 | 1.63 | 1.73 |
| Sep 22, 2026 | 1.56 | 1.65 | 1.73 |
| Sep 21, 2026 | 1.54 | 1.63 | 1.71 |
| Sep 18, 2026 | 1.59 | 1.67 | 1.76 |
| Sep 17, 2026 | 1.62 | 1.70 | 1.79 |
GANX shares rose +3.49% in Thursday, September 17, 2026's trading session, rising from a previous close of $1.72 to move at $1.78. The stock demonstrated notable intraday movement (see GANX's key stats for a full breakdown), fluctuating between $1.74 and $1.79, a +3.17% trading range. While recent weeks have seen some volatility, GANX has managed to secure a -2.20% drop over the past 2 weeks. The upward price movement was accompanied by increased trading volume, with approximately 340.03K shares changing hands, 75.3K more than the previous session. This amounted to $605.25K in total market activity.
Will GANX Continue Its Downward Trend?
According to analyst ratings and projections for GANX, Gain Therapeutics, Inc. shares are anticipated to decrease by -7.47%, potentially reaching $1.66 per share by September 30, 2026. Short-term technical indicators currently suggest a neutral sentiment for GANX. For deeper insights, view our sentiment analysis on AAPL covering social and institutional perspectives. However, the stock has recorded 14 positive trading days within the past 30 sessions. Based on the GANX stock forecast, now is not the best time to buy GANX stock because its current trading price is +14.49% above our predicted value, hinting at a possible undervaluation. For deeper insights, view our sentiment analysis on GANX covering social and institutional perspectives.
GANX Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into GANX's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 47.34% to 48.60%) suggest the stock is in a neutral to slightly bearish momentum phase. The 50-day RSI, at 48.46%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 48.81%, maintains a neutral outlook for the long term. Insights into GANX's shareholder base show how institutional investors are positioning themselves during these momentum shifts
Gain Therapeutics Short-Term Forecasts
GANX Forecast For Next 5 Days
Our algorithm anticipates Gain Therapeutics (GANX) stock could hit $1.52 by Sep 24, 2026. This represents a -14.48% fall from today's price, following a -7.01% change over the past five days.
GANX Forecast For Next 30 Days
Based on analysis of market trends, the outlook for Gain Therapeutics, Inc. (GANX) stock over the next 30 days is largely negative. Price forecasts suggest an average target of $1.50, which would mean a -15.73% decrease from the current price of $1.78. Projections for this period range from a high of $1.83 to a low of $1.22.
GANX Forecast For Next 90 Days
Our proprietary market analysis suggests predictions for Gain Therapeutics's price over the next three months point to a rise. GANX stock is expected to peak at $10.97 on Oct 07, 2026 before potentially dipping to $7.24 on Dec 10, 2026. On average, GANX is likely to trade around $9.40 in the coming 90 days.
Gain Therapeutics Stock Forecast 2025
Based on our predictive models, Gain Therapeutics (GANX) is expected to trade between $7.24 and $11.10 throughout 2026. This would result in an average price of $9.54, potentially offering investors a +435.96% return from current levels.
Gain Therapeutics, Inc. Monthly Forecast 2026–2027
September 2026
According to our latest forecast models, Gain Therapeutics, Inc. (GANX) is positioned to show a strong performance in September 2026. The price is predicted to move between $8.37 and $9.99, settling at an average of $9.14. This could translate to a +413.48% gain.
October 2026
Based on current market signals, Gain Therapeutics, Inc. is projected to trend october 2026. We forecast a trading range from $9.31 to $10.97, with a likely average price of $10.33. Investors could expect a potential return of +480.34%.
November 2026
Our predictive algorithms indicate Gain Therapeutics, Inc. stock may see a shift in November 2026. The expected range spans $7.78–$10.27, with an average target of $9.19. This represents a positive outlook and a possible gain of +416.29%.
December 2026
Analyzing established trends, Gain Therapeutics, Inc. looks set to move in December 2026. Projections place the stock between $7.24 and $11.10, averaging around $9.29. This suggests a +421.91% gain from current levels.
January 2027
Market indicators suggest Gain Therapeutics, Inc. could experience notable changes during January 2027. Prices could fluctuate within $5.92 to $11.07, with a midpoint forecast of $9.26. The stock might deliver a +420.22% gain.
February 2027
Forecasting for February 2027, models estimate that Gain Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $6.03 and $12.25, averaging $10.12. This signals a positive trajectory with potential returns around +468.54%.
March 2027
According to our latest forecast models, Gain Therapeutics, Inc. (GANX) is positioned to show a strong performance in March 2027. The price is predicted to move between $3.38 and $12.82, settling at an average of $10.09. This could translate to a +466.85% gain.
April 2027
Based on current market signals, Gain Therapeutics, Inc. is projected to trend april 2027. We forecast a trading range from $2.10 to $10.85, with a likely average price of $7.84. Investors could expect a potential return of +340.45%.
May 2027
Our predictive algorithms indicate Gain Therapeutics, Inc. stock may see a shift in May 2027. The expected range spans $1.30–$14.28, with an average target of $7.80. This represents a positive outlook and a possible gain of +338.20%.
June 2027
Analyzing established trends, Gain Therapeutics, Inc. looks set to move in June 2027. Projections place the stock between $0.03 and $14.02, averaging around $7.31. This suggests a +310.67% gain from current levels.
July 2027
Market indicators suggest Gain Therapeutics, Inc. could experience notable changes during July 2027. Prices could fluctuate within $0.00 to $15.27, with a midpoint forecast of $8.01. The stock might deliver a +350.00% gain.
August 2027
Forecasting for August 2027, models estimate that Gain Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $0.00 and $16.52, averaging $8.00. This signals a positive trajectory with potential returns around +349.44%.
September 2027
According to our latest forecast models, Gain Therapeutics, Inc. (GANX) is positioned to show a strong performance in September 2027. The price is predicted to move between $0.00 and $17.66, settling at an average of $8.22. This could translate to a +361.80% gain.
GANX's history of dividends and stock splits also plays a role in long-term investor confidence.

